GlassScriptPhysician profile
Kara H Mayes
NPI 1205062759
$4,514.11
in general payments reported to CMS, 2019-2025
18 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,515 · 2020: $45.02 · 2021: $656 · 2022: $725 · 2023: $823 · 2024: $547 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.55 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,106.50 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $629.62 | 2021-2024 | Zepbound, Mounjaro |
| Koya Medical, INC. | $141.19 | 2023 | Dayspring |
| Vivus LLC | $120.29 | 2025 | Qsymia |
| Currax Pharmaceuticals LLC | $107.15 | 2020-2024 | Contrave |
| Abbvie INC. | $76.02 | 2021 | |
| Abbott Laboratories | $62.90 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $57.31 | 2021 | |
| Tactile Systems Technology INC | $40.33 | 2022 | |
| Amarin Pharma, INC. | $38.89 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.12 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.85 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $18.88 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.48 | 2023 | |
| Genzyme Corporation | $17.42 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $17.41 | 2021 | |
| Glaxosmithkline, LLC. | $15.75 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Mayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.